Efficacy and Safety Study of Dermal-Living Skin Replacement to Treat Diabetic Foot Ulcers

Inclusion Criteria:

• Have Type I or Type II diabetes
• Signed informed consent obtained from subject or legal guardian/representative prior to the first study intervention.
• Age ≥ 18 and < 85 years old at the time the informed consent is signed.

• Subjects will have a diabetic ulcer on the lower extremity, with the ulcer having all of the following characteristics:

  1. Full-thickness plantar ulcers (fore and mid foot only);
  2. Non-infected as determined by clinical assessment;
  3. Neuropathic as determined by monofilament assessment;
  4. Area ≥ 1.0 cm2 ≤ 25.0 cm2 post-debridement;
  5. Has been present for at least 8 weeks under a physician's observation at the time of enrollment;
  6. Extends through the dermis but without tendon, muscle, capsule or bone exposure.
• Subjects will have only one diabetic foot ulcer on the target limb.
• Subjects will have either insulin-dependent or non-insulin-dependent diabetes mellitus (Type I or Type II, respectively) with a HbA1C value in the range of 6% to 12%.
• The ulcer bed at the time of enrollment must be free of all necrotic and infected soft and bony tissue as determined by clinical examination (no evidence of probing to bone) and by X-ray films.
• Ankle-brachial systolic pressure index between 0.7 and 1.3. If the value is > 1.3, then a transcutaneous partial pressure of oxygen (TcPO2) of ≥ 40 mmHg OR a toe pressure of ≥ 50 mmHg must be obtained for subject to be eligible.
• Female subjects must have a negative serum pregnancy test prior to the first treatment.

Exclusion Criteria:

• Known or suspected disease of the immune system currently under investigation, other than Diabetes Mellitus.
• Active or untreated malignancy or active, uncontrolled connective tissue disease.
• Treatment with immunosuppressive or chemotherapeutic agents, radiotherapy or corticosteroids less than 30 days before enrollment.
• Presence of necrosis, purulence or sinus tracts that cannot be removed by treatment.
• Has undergone a revascularization procedure aimed at increasing blood flow in the treatment target limb < 4 weeks prior to enrollment.
• Active febrile illness (fever ≥ 38.0 ºC p.o.).
• Renal or liver impairment as indicated by serum creatinine levels and liver function tests three or more times higher than the normal values.
• Osteomyelitis diagnosed by exposed bone and by radiological investigations.
• Subject has an active Charcot as determined by the clinical examination (new local pain, evidence of swelling and warmth).
• Subjects who refuse or who are unable to participate in all screening procedures, or to comply with the requirements of the study.
• Use of other investigational products at the time of enrollment or during the study.
• The use of any topical treatments, other than SOC, in or on the surface of the target ulcer at the time of enrollment.
• Subjects who have been enrolled in any investigational clinical trial within 30 days of the screening visit.
• Currently pregnant or lactating, or planning a pregnancy to occur during the study period.
• Known allergic reactions, including dermatological hypersensitivity, to any study product components.
• Recent or current history of alcohol or drug abuse.
• Subjects who, in the opinion of the Investigator, represent poor medical, psychological or psychiatric risks for whom therapy with an investigational product would be unwise.